Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

RT With Or Without Temozolomide (E3F05)

Stage Phase 3

Sponsor ECOG-ACRIN

Modality small molecule

Class alkylating chemotherapy

Target DNA alkylation (O6-guanine)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/api/v2/studies?query.cond=glioma&query.term=IDH

ClinicalTrials.gov API v2: IDH-mutant glioma interventional records plus 34 individual records, retrieved 11.07.2026 (registry fields as entered by sponsors)

Brief source I16

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT00978458

Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT00978458

Registry NCT00978458

Phase Phase 3

Status Active, not recruiting

Enrollment 540

Start 2009-11-17

Primary completion 2026-12-31

Study completion 2026-12-31

Catalyst Primary completion. 12.31.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.